SCHEMBL3003783

SCHEMBL3003783

COc1ccccc1-c1csc(N2CCC(S(=O)(=O)c3cc(Cl)cc(Cl)c3)CC2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.50
AR P10275 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.42
RAB9A P51151 4/20 0.42
MAPT P10636 3/20 0.42
NPC1 O15118 2/20 0.42
REV1 Q9UBZ9 1/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KMT2A Q03164 2/20 0.40
CDC25A P30304 1/20 0.39
CDC25B P30305 1/20 0.39
CDC25C P30307 1/20 0.39
DUSP3 P51452 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
UCHL1 P09936 1/20 0.39
USP30 Q70CQ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005423 0.94 KDM1A (0.57) KDM1AARSMN1; SMN2RAB9AMAPT
SCHEMBL3010988 0.92 AR (0.46) KDM1AARSMN1; SMN2RAB9AMAPT
SCHEMBL3012677 0.90 AR (0.46) KDM1AARSMN1; SMN2RAB9AMAPT
SCHEMBL3018798 0.89 AR (0.48) KDM1AARSMN1; SMN2RAB9AMAPT
SCHEMBL3007408 0.89 AR (0.49) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3014442 0.89 REV1 (0.51) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3004385 0.89 AR (0.48) KDM1AARSMN1; SMN2RAB9AMAPT
SCHEMBL3018735 0.88 AR (0.46) KDM1AARSMN1; SMN2RAB9AMAPT
SCHEMBL3016521 0.87 AR (0.54) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3010419 0.87 MAPT (0.52) ARSMN1; SMN2RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM1A 3548/4885AR 3801/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.